Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Completes Enrollment In SAFFRON Ph III Trial
    HUTCHMED Completes Enrollment In SAFFRON Ph III Trial

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181024/0/en/HUTCHMED-Announces-Enrollment-Completed-of-SAFFRON-Global-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-for-Certain-Lung-Cancer-Patients-with-MET-Overexpression-and-or-Ampli.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Hutchmed Showcases Clinical Data At Esmo Congress 2025
    Hutchmed Showcases Clinical Data At Esmo Congress 2025

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China
    HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136084/0/en/HUTCHMED-Completes-Patient-Enrollment-of-SANOVO-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-as-a-First-Line-Therapy-for-Certain-Lung-Cancer-Patients-in-China.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Hutchmed Gets China Nod for Orpathys + Tagrisso Combo
    Hutchmed Gets China Nod for Orpathys + Tagrisso Combo

    30 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/30/3107244/0/en/HUTCHMED-Announces-China-Approval-for-ORPATHYS-in-Combination-with-TAGRISSO-for-the-Treatment-of-Lung-Cancer-Patients-with-MET-Amplification-After-Progression-on-First-Line-EGFR-In.html

    GLOBENEWSWIRE
    30 Jun 2025
    Share Share
    Hutchmed Completes Patient Enrollment for Savolitinib Study
    Hutchmed Completes Patient Enrollment for Savolitinib Study

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/22/3065080/0/en/HUTCHMED-Completes-Patient-Enrollment-of-a-Phase-II-Registration-Study-of-Savolitinib-in-Gastric-Cancer-in-China.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025
    HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025

    19 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045892/0/en/HUTCHMED-Highlights-Savolitinib-SAVANNAH-Phase-II-and-Other-Data-at-European-Lung-Cancer-Congress-2025.html

    GLOBENEWSWIRE
    19 Mar 2025
    Share Share